L. Austin Doyle

2.2k total citations
35 papers, 922 citations indexed

About

L. Austin Doyle is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, L. Austin Doyle has authored 35 papers receiving a total of 922 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in L. Austin Doyle's work include PI3K/AKT/mTOR signaling in cancer (6 papers), Cancer Treatment and Pharmacology (6 papers) and Lung Cancer Treatments and Mutations (4 papers). L. Austin Doyle is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (6 papers), Cancer Treatment and Pharmacology (6 papers) and Lung Cancer Treatments and Mutations (4 papers). L. Austin Doyle collaborates with scholars based in United States, United Kingdom and Canada. L. Austin Doyle's co-authors include Koen van Besien, Janet Dancey, Sonali M. Smith, Patrick J. Stiff, Theodore Karrison, Barbara Pro, Everett E. Vokes, Bert H. O’Neil, Scott E. Smith and Eric P. Lester and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

L. Austin Doyle

30 papers receiving 890 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L. Austin Doyle United States 12 407 338 247 236 200 35 922
Preston D. Steen United States 18 579 1.4× 259 0.8× 125 0.5× 120 0.5× 329 1.6× 47 1.0k
Joji Yamamoto Japan 17 337 0.8× 171 0.5× 216 0.9× 381 1.6× 156 0.8× 39 997
Chueh‐Chuan Yen Taiwan 19 386 0.9× 203 0.6× 173 0.7× 221 0.9× 377 1.9× 58 930
Alexis D. Leal United States 15 545 1.3× 244 0.7× 188 0.8× 163 0.7× 128 0.6× 57 888
Sheeja T. Pullarkat United States 13 508 1.2× 234 0.7× 272 1.1× 86 0.4× 122 0.6× 43 980
E.D. Kreuser Germany 18 797 2.0× 202 0.6× 207 0.8× 212 0.9× 187 0.9× 48 1.2k
Masafumi Takimoto Japan 13 402 1.0× 213 0.6× 156 0.6× 131 0.6× 171 0.9× 40 815
H. J. Illiger Germany 11 555 1.4× 386 1.1× 91 0.4× 121 0.5× 266 1.3× 28 974
Josep Gumà Spain 18 202 0.5× 386 1.1× 195 0.8× 524 2.2× 210 1.1× 64 1.1k
Joo Han Lim South Korea 18 393 1.0× 335 1.0× 85 0.3× 94 0.4× 144 0.7× 61 867

Countries citing papers authored by L. Austin Doyle

Since Specialization
Citations

This map shows the geographic impact of L. Austin Doyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Austin Doyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Austin Doyle more than expected).

Fields of papers citing papers by L. Austin Doyle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Austin Doyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Austin Doyle. The network helps show where L. Austin Doyle may publish in the future.

Co-authorship network of co-authors of L. Austin Doyle

This figure shows the co-authorship network connecting the top 25 collaborators of L. Austin Doyle. A scholar is included among the top collaborators of L. Austin Doyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Austin Doyle. L. Austin Doyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mittra, Arjun, Geraldine O’Sullivan Coyne, Sarina A. Piha‐Paul, et al.. (2019). Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors.. Journal of Clinical Oncology. 37(15_suppl). 3067–3067. 8 indexed citations
2.
Al‐Kali, Aref, Ibrahim Aldoss, Carrie Strand, et al.. (2019). A phase II study (NCI9775) of sapanisertib (MLN0128/TAK-228) in relapsed and/or refractory acute lymphoblastic leukemia (ALL): Interim analysis.. Journal of Clinical Oncology. 37(15_suppl). e18506–e18506. 5 indexed citations
3.
Paik, Paul K., Linda S. Ahn, Michelle S. Ginsberg, et al.. (2018). P2.13-44 Targeting NFE2L2 Mutations in Advanced Squamous Cell Lung Cancers with the TORC1/2 Inhibitor TAK-228. Journal of Thoracic Oncology. 13(10). S816–S816.
4.
5.
Wilky, Breelyn A., Michelle A. Rudek, Dan Laheru, et al.. (2014). A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. British Journal of Cancer. 112(1). 24–31. 35 indexed citations
6.
Liu, Xiaochun, Patricia LoRusso, Monica Mita, et al.. (2014). Incidence of Mucositis in Patients Treated With Temsirolimus-Based Regimens and Correlation to Treatment Response. The Oncologist. 19(4). 426–428. 9 indexed citations
7.
Rajan, Arun, Sean Khozin, Anish Thomas, et al.. (2013). The Evaluation of Selumetinib a MEK-Inhibitor with and without the Addition of Erlotinib in KRAS Mutated Non-Small Cell Lung Cancer. Annals of Oncology. 24. i7–i7. 1 indexed citations
8.
Garrett‐Mayer, Elizabeth, Elihu H. Estey, Michelle A. Rudek, et al.. (2012). Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica. 97(11). 1736–1742. 49 indexed citations
9.
Bekaii‐Saab, Tanios, Mitch A. Phelps, Xiaobai Li, et al.. (2011). Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers. Journal of Clinical Oncology. 29(17). 2357–2363. 232 indexed citations
10.
Smith, Sonali M., Koen van Besien, Theodore Karrison, et al.. (2010). Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium. Journal of Clinical Oncology. 28(31). 4740–4746. 165 indexed citations
11.
Barber, P.V., et al.. (2006). Erythema gyratum repens with pulmonary tuberculosis. British Journal of Dermatology. 98(4). 465–468. 9 indexed citations
12.
Tkaczuk, Katherine H. R., William C. Zamboni, Nancy Tait, et al.. (2000). Phase I study of docetaxel and topotecan in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 46(6). 442–448. 6 indexed citations
13.
Zamboni, William C., Merrill J. Egorin, David A. Van Echo, et al.. (2000). Pharmacokinetic and Pharmacodynamic Study of the Combination of Docetaxel and Topotecan in Patients With Solid Tumors. Journal of Clinical Oncology. 18(18). 3288–3294. 24 indexed citations
14.
Doyle, L. Austin. (1991). Myxoedema: Some Early Reports and Contributions by British Authors, 1873–1898. Journal of the Royal Society of Medicine. 84(2). 103–106. 11 indexed citations
15.
Doyle, L. Austin, L J McWilliam, & P S Hasleton. (1988). Giant cell arteritis with pulmonary involvement. British Journal of Diseases of the Chest. 82(1). 88–92. 16 indexed citations
16.
Doyle, L. Austin. (1988). Lardaceous Disease: Some Early Reports by British Authors (1722–1879). Journal of the Royal Society of Medicine. 81(12). 729–731. 10 indexed citations
17.
Doyle, L. Austin. (1987). Hypertrophic osteoarthropathy: four early reports by British authors (1889-97).. Thorax. 42(8). 561–564. 4 indexed citations
18.
Rademaker, Marius, et al.. (1985). Hypertrophic osteoarthropathy, spider naevi and oestrogen hyperexcretion associated with adenocarcinoma. Postgraduate Medical Journal. 61(719). 827–828. 1 indexed citations
19.
Doyle, L. Austin, et al.. (1983). Erythema and Desquamation After High-Dose Methotrexate. Annals of Internal Medicine. 98(5_Part_1). 611–612. 58 indexed citations
20.
Doyle, L. Austin, et al.. (1960). TRETAMINE IN THE TREATMENT OF INOPERABLE LUNG CANCER. The Lancet. 275(7117). 206–207. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Preston D. Steen Breakdown of academic impact, for papers by Joji Yamamoto Breakdown of academic impact, for papers by Chueh‐Chuan Yen Breakdown of academic impact, for papers by Alexis D. Leal Breakdown of academic impact, for papers by Sheeja T. Pullarkat Breakdown of academic impact, for papers by E.D. Kreuser Breakdown of academic impact, for papers by Masafumi Takimoto Breakdown of academic impact, for papers by H. J. Illiger Breakdown of academic impact, for papers by Josep Gumà Breakdown of academic impact, for papers by Joo Han Lim
Rankless by CCL
2026